The trial aimed to determine the safety, efficacy, tolerability and pharmacokinetics of X-Excite in men on side by side study with Pfizer’s Viagra.
Reportedly, the study evaluated total 24 patients in which half received X-Excite, and the other half received Viagra.
Global Health president and CEO Hassan Salari said they are very pleased to complete their patients’ enrollment in which no one dropped out of the trials or had to be replaced.
"The testing went well and now we are looking forward to the final results and completed data report, before entering into discussion for partnership with major pharmaceutical companies," Salari said.